SCHEMBL7224988

SCHEMBL7224988

CC(=O)c1ccc(NCCC(C)C)c(N)c1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.58
PTGER4 P35408 4/20 0.51
GAA P10253 3/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
THRB P10828 1/20 0.50
HPGD P15428 1/20 0.50
HTT P42858 1/20 0.50
GFER P55789 1/20 0.50
PLEC Q15149 1/20 0.50
LMNA P02545 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
PRSS1 P07477 10/20 0.49
HSD17B10 Q99714 1/20 0.46
CREBBP Q92793 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3440911 0.85 PRKCI (0.61) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL22931144 0.82 PTGER4 (0.71) PTGER4GAAKDM4EALDH1A1MAPT
SCHEMBL5591978 0.82 HPGD (0.48) PTGER4GAAKDM4EALDH1A1MAPT
SCHEMBL2082009 0.80 KDM4E (0.76) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL14457852 0.79 SMN1; SMN2 (0.54) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL5104664 0.79 PTGER4 (0.43) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL11542994 0.78 PRKCI (0.60) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL7230677 0.78 HCAR3 (0.59) PTGER4ALDH1A1MAPTLMNASMN1; SMN2
SCHEMBL5591721 0.78 PTGER4 (0.39) PRKCIPTGER4GAAKDM4EALDH1A1
SCHEMBL5591910 0.77 L3MBTL1 (0.45) PTGER4GAAKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6506738-B1 Treatment of viral infections. More particularly, the invention provides benzimidazolone derivatives for the treatment of respiratory syncytial virus infection. BRISTOL-MYERS SQUIBB COMPANY 2003-01-14 US disclosed
WO-2002026228-A1 BENZIMIDAZOLONE ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-04-04 WO disclosed